|
Jan 5
|
Private equity firms are HUTCHMED (China) Limited's (LON:HCM) biggest owners and were rewarded after market cap rose by UK£120m last week
|
|
Jan 2
|
Hutchmed divests 45% interest in Shanghai Hutchison for $608M
|
|
Jan 2
|
HUTCHMED Announces NDA Acceptance in China with Priority Review Status for ORPATHYS® and TAGRISSO® Combination in Lung Cancer Patients with MET amplification After Progression on First-Line EGFR Inhibitor Therapy
|
|
Jan 1
|
HUTCHMED Announces US$608 million Divestment of Non-Core Joint Venture
|
|
Oct 1
|
HUTCHMED (China) (LON:HCM) shareholders are up 17% this past week, but still in the red over the last three years
|
|
Sep 26
|
Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing
|
|
Aug 30
|
HUTCHMED Provides Update on Fruquintinib for Second-Line Gastric Cancer in China
|
|
Aug 28
|
HUTCHMED (China) Limited (HCM): A Cheap Pharmaceutical Stock to Buy According to Short Sellers
|
|
Aug 21
|
HUTCHMED to Host Expert Call to discuss Immune Thrombocytopenia
|
|
Jul 29
|
HUTCHMED (China) Limited's (LON:HCM) last week's 6.4% decline must have disappointed private equity firms who have a significant stake
|
|
Jun 26
|
HUTCHMED to Announce 2024 Half-Year Financial Results
|
|
Jun 24
|
Save the Date: HUTCHMED to Present R&D Updates on July 9, 2024
|
|
Jun 21
|
HUTCHMED Announces European Commission Approval for FRUZAQLA® (fruquintinib) Received by Takeda
|
|
Jun 7
|
HUTCHMED Initiates Phase I Trial of Menin Inhibitor HMPL-506 in Patients with Hematological Malignancies in China
|
|
May 24
|
HUTCHMED Highlights Presentations at the 2024 ASCO Annual Meeting
|
|
May 17
|
HUTCHMED announces retirement of Chairman, appointment of new Chairman and change of members of board committees
|
|
May 17
|
HUTCHMED Highlights Sovleplenib Phase III ESLIM-01 Study and Hematological Malignancy Programs Data to be Presented at the upcoming EHA2024 Congress
|
|
May 14
|
HUTCHMED Initiates the RAPHAEL Registrational Phase III Trial of HMPL-306 for Patients with IDH1- and/or IDH2-Mutated Relapsed/Refractory Acute Myeloid Leukemia in China
|
|
May 14
|
HUTCHMED Initiates Phase II/III Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naïve Pancreatic Ductal Adenocarcinoma in Collaboration with Hengrui
|
|
May 8
|
HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee
|